Historique
Périodique
Predictors of benzodiazepine discontinuation in subjects manifesting complicated dependence
(Facteurs prédictifs de l'arrêt de la consommation de benzodiazépines chez des sujets souffrant de problèmes de dépendance complexes)
Auteur(s) :
VORMA, H. ;
NAUKKARINEN H. ;
SARNA S. J. ;
KUOPPASALMI, K.
Année
2005
Page(s) :
499-510
Langue(s) :
Anglais
Refs biblio. :
36
Domaine :
Plusieurs produits / Several products
Thésaurus mots-clés
DEPENDANCE
;
FACTEUR PREDICTIF
;
BENZODIAZEPINES
;
SEVRAGE
;
PSYCHOPATHOLOGIE
;
POLYCONSOMMATION
Note générale :
Substance Use and Misuse, 2005, 40, (4), 499-510
Note de contenu :
tabl.
Résumé :
ENGLISH :
We described characteristics of subjects with benzodiazepine dependence that was typically complicated by harmful and hazardous alcohol use or high benzodiazepine doses, and assessed predictors of successful discontinuation of benzodiazepines for this group. Seventy-six patients who participated in a randomized clinical trial of two different gradual withdrawal treatment approaches were assessed. The trial was conducted between February 1995 and July 1999. The mean age +SD of subjects was 40.0+9.6 years, 55% were male, 38% were married or cohabiting, and 70% had received more than nine years of education. The median benzodiazepine dose was 35 mg /day (range 2.5180) in diazepam equivalents. The median duration of benzodiazepine use was 84 (range 8360) months. Subjects with lower benzodiazepine doses and no previous withdrawal attempts were more successful at benzodiazepine discontinuation. Cluster B personality/borderline personality disorder was associated with an inability to stop benzodiazepine use and with dropping out of treatment. Alcohol userelated disorders or other psychiatric diagnoses were not associated with outcome. Further studies on predictors of successful benzodiazepine discontinuation in different populations are required. Patients manifesting cluster B personality/borderline personality disorder and benzodiazepine dependence may need concomitant treatment for their personality disorders to benefit from benzodiazepine discontinuation treatment. (Review' s abstract)
Affiliation :
National Public Health Institute, Department for Mental Health and Alcohol Research, Mannerheimintie 166, FIN-00300, Helsinki. E-mail : helena.vorma@hus.fi
Finlande. Finland.
Finlande. Finland.